← Back to all news
← Terug naar alle nieuws
← Back to all news (FR)

11/02/2021 - Alychlo investing in potential breakthroughs of cancer treatments

Alychlo investing in potential breakthroughs of cancer treatments

Alychlo investing in potential breakthroughs of cancer treatments

Droia Ventures has supported Series C financing of Cyteir Therapeutics for the advance Clinical Trials of Lead RAD51, a potential breakthrough forcancer treatments.

Alychlo is a proud partner of Droia since 2014 and has supported Droia in each of their funds since then.

Find the full press release on: Droia Ventures